Northern Exposure PR

We are the leading public relations company serving the life science, pharmaceutical and technology industries.



Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.



Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management



Northern Exposure Public Relations is uniquely skilled in assisting clients in all public relations requirements

Meet Our Team

Richard Kerns

Managing Director

Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.

Edward Dutton

Vice President

Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.

Sarah Houlton

Technical Consultant in Residence

Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.

Our Services

NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:

Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more.

Contact us today to find out how we can assist you

Our Clients

Client News

02/06/2020 Catalent Appoints Charles Lickfold as Chief Information Officer

03/06/2020 Vectura Expands Business Development Team with Three Global Appointments

08/06/2020 Vectura signs agreement with Aerami Therapeutics Inc. to Support the Development of Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension

15/06/2020 Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate

18/06/2020 Cambrex Names Thomas Loewald as Chief Executive Officer

22/06/2020 Catalent Partners with ViralClear Pharmaceuticals on Potential Treatment for COVID-19

25/06/2020 Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

30/06/2020 Catalent Expands Beauty and Plant-Based Consumer Health Softgel Capabilities at its Facilities in Canada and Brazil

01/07/2020 Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility

01/07/2020 Catalent Completes Purchase of Pharmaceutical Packaging Facility in Shiga, Japan

07/07/2020 SGS Joins with Biophytis to Launch Its International Clinical Trial of COVID-19 Related Respiratory Failure Treatment

16/07/2020 Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab

17/07/2020 SGS’s Quality, Expertise & Reliability Recognized at CRO Leadership Awards 2020

21/07/2020 Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in Limoges, France

29/07/2020 Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

04/08/2020 Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

06/08/2020 Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy

24/08/2020 Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

02/09/2020 Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility

02/09/2020 SGS Enrolls First Patient into Biophytis COVA Clinical Study, a COVID-19 Related Acute Respiratory Failure Treatment Clinical Trial

08/09/2020 Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology

09/09/2020 Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland

14/09/2020 Vectura Partners with Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage

21/09/2020 T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy

24/09/2020 Catalent Acquires New Biologics Facility to Create North American Clinical Manufacturing Center of Excellence

28/09/2020 Catalent Supports Rapid Development and Supply of Nocion Therapeutics’ Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology

01/10/2020 Catalent Launches OneXpress™ Solution to Accelerate Oral Dosage Products from Clinic to Launch

01/10/2020 Catalent Wins Scottish Engineering Vice President Award for Excellence

12/10/2020 Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh

19/10/2020 Catalent Launches OptiGel® DR, a Delayed/Enteric Release Softgel for Pharmaceutical and Nutraceutical Applications

22/10/2020 Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®

29/10/2020 Catalent to Acquire Cell Therapy Manufacturing Facility from Bone Therapeutics

05/11/2020 Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership with Catalent

17/11/2020 Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the U.S.

18/11/2020 SGS Increases its Capacity for Human Challenge Studies

23/11/2020 Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

30/11/2020 SGS Welcomes First Participants onto COVID-19 Clinical Trials in US

30/11/2020 Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma

03/12/2020 Catalent to Invest $10 Million to Expand High Potency Containment Capabilities For Micronization

07/12/2020 Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

10/12/2020 Catalent Appoints Nakaya Matsumaru as General Manager of its New Clinical Supply Facility in Shiga, Japan

14/12/2020 Vectura Expands Capabilities to Handle and Develop Highly Potent Inhaled Drugs at its Facility in Chippenham, U.K.

17/12/2020 Vectura earns $11m milestone as Hikma receives US FDA approval for generic Advair Diskus®

Upcoming Events

NEPR will be attending the following events:

None at present – at this time our thoughts go out to all who have been affected by the current global situation, and we hope we will be meeting people when it is safe to do so.

[wolf_tweet username=”NrthnExposurePR” type=”single|list” count=”3″]